Potential of novel anticancer vaccine demonstrated in Atalante-1 NSCLC trial

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Sep 20 / Springer Healthcare

Potential of novel anticancer vaccine demonstrated in Atalante-1 NSCLC trial

Oncology Lung Cancer ESMO-2021

Description

Gilberto Lopes comments on the Atalante-1 trial of the anticancer vaccine OSE-2101 in previously treated patients with HLA-A2+ advanced non-small-cell lung cancer, explaining why he is excited to see future studies with the agent.

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.